Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.

Mizandari M, Paksashvili N, Kikodze N, Azrumelashvili T, Pantsulaia I, Shanava K, Janikashvili N, Chikovani T.

Immunotherapy. 2017 Oct;9(13):1067-1069. doi: 10.2217/imt-2017-0069.

PMID:
29032738
2.

Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia.

Audia S, Santegoets K, Laarhoven AG, Vidarsson G, Facy O, Ortega-Deballon P, Samson M, Janikashvili N, Saas P, Bonnotte B, Radstake TR.

Clin Exp Immunol. 2017 May;188(2):275-282. doi: 10.1111/cei.12935. Epub 2017 Feb 28.

3.

Immunotherapeutic Targeting in Autoimmune Diseases.

Janikashvili N, Samson M, Magen E, Chikovani T.

Mediators Inflamm. 2016;2016:1432702. doi: 10.1155/2016/1432702. Epub 2016 Dec 15. No abstract available.

4.

B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia.

Audia S, Rossato M, Trad M, Samson M, Santegoets K, Gautheron A, Bekker C, Facy O, Cheynel N, Ortega-Deballon P, Boulin M, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Janikashvili N, Saas P, Radstake T, Bonnotte B.

J Autoimmun. 2017 Feb;77:89-95. doi: 10.1016/j.jaut.2016.11.002. Epub 2016 Nov 15.

PMID:
27863820
5.

Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation.

Mizandari M, Azrumelashvili T, Paksashvili N, Kikodze N, Pantsulaia Ia, Janikashvili N, Chikovani T.

Case Reports Hepatol. 2016;2016:6843121. doi: 10.1155/2016/6843121. Epub 2016 Aug 8.

6.

Involvement and prognosis value of CD8(+) T cells in giant cell arteritis.

Samson M, Ly KH, Tournier B, Janikashvili N, Trad M, Ciudad M, Gautheron A, Devilliers H, Quipourt V, Maurier F, Meaux-Ruault N, Magy-Bertrand N, Manckoundia P, Ornetti P, Maillefert JF, Besancenot JF, Ferrand C, Mesturoux L, Labrousse F, Fauchais AL, Saas P, Martin L, Audia S, Bonnotte B.

J Autoimmun. 2016 Aug;72:73-83. doi: 10.1016/j.jaut.2016.05.008. Epub 2016 May 25.

PMID:
27236507
7.

T Lymphocyte Plasticity in Autoimmunity and Cancer.

Janikashvili N, Chikovani T, Audia S, Bonnotte B, Larmonier N.

Biomed Res Int. 2015;2015:540750. doi: 10.1155/2015/540750. Epub 2015 Oct 25. No abstract available.

8.

HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.

Kikodze N, Mazmishvili K, Iobadze M, Rekhviashvili Kh, Nanava N, Pantsulaia I, Mizandari M, Janikashvili N, Chikovani T.

Georgian Med News. 2015 Sep;(246):78-84. Review.

PMID:
26355320
9.

Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes.

Janikashvili N, Trad M, Gautheron A, Samson M, Lamarthée B, Bonnefoy F, Lemaire-Ewing S, Ciudad M, Rekhviashvili K, Seaphanh F, Gaugler B, Perruche S, Bateman A, Martin L, Audia S, Saas P, Larmonier N, Bonnotte B.

J Allergy Clin Immunol. 2015 Jun;135(6):1614-24.e4. doi: 10.1016/j.jaci.2014.12.1868. Epub 2015 Jan 25.

PMID:
25630940
10.

Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia.

Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, van den Broek T, Facy O, Ortega-Deballon P, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Samson M, Trad M, Lorcerie B, Janikashvili N, Saas P, Bonnotte B, Radstake TR.

Blood. 2014 Oct 30;124(18):2858-66. doi: 10.1182/blood-2014-03-563445. Epub 2014 Sep 16.

11.

Does tocilizumab indeed reduce the frequency of Th17 cells? Comment on the article by Thiolat et al.

Samson M, Audia S, Ornetti P, Maillefert JF, Janikashvili N, Bonnotte B.

Arthritis Rheumatol. 2014 Sep;66(9):2639-40. doi: 10.1002/art.38718. No abstract available.

12.

PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Hanke NT, LaCasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Eur J Immunol. 2014 Aug;44(8):2489-2499. doi: 10.1002/eji.201343803. Epub 2014 May 23.

13.

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Cancer Res. 2014 Jan 1;74(1):104-18. doi: 10.1158/0008-5472.CAN-13-1545. Epub 2013 Nov 6.

14.

Is TNF-α really involved in giant cell arteritis pathogenesis?

Samson M, Audia S, Janikashvili N, Bonnotte B.

Ann Rheum Dis. 2014 Jan;73(1):e1. doi: 10.1136/annrheumdis-2013-204462. Epub 2013 Aug 29. No abstract available.

PMID:
23989985
15.

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

Audia S, Samson M, Mahévas M, Ferrand C, Trad M, Ciudad M, Gautheron A, Seaphanh F, Leguy V, Berthier S, Salles B, Martin L, Lorcerie B, Ortega-Deballon P, Facy O, Caillot D, Soudry-Faure A, Michel M, Godeau B, Larmonier N, Saas P, Janikashvili N, Bonnotte B.

Blood. 2013 Oct 3;122(14):2477-86. doi: 10.1182/blood-2013-03-491415. Epub 2013 Aug 20.

16.

Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells.

Samson M, Audia S, Martin L, Janikashvili N, Bonnotte B.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S65-73. Epub 2013 Apr 19. Review.

PMID:
23663684
17.

Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al.

Samson M, Audia S, Janikashvili N, Bonnotte B.

Ann Rheum Dis. 2013 May;72(5):e3. doi: 10.1136/annrheumdis-2013-203439. Epub 2013 Mar 8. No abstract available.

PMID:
23475980
18.

Reply: To PMID 22833233.

Samson M, Janikashvili N, Martin L, Audia S, Bonnotte B.

Arthritis Rheum. 2013 Apr;65(4):1134-5. doi: 10.1002/art.37863. No abstract available.

19.

Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells.

Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, Kartchner J, Janikashvili N, Bonnotte B, Larmonier N, Katsanis E.

J Leukoc Biol. 2012 Nov;92(5):987-97. doi: 10.1189/jlb.0911465. Epub 2012 Aug 13.

20.

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.

Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, Ciudad M, Leguy V, Berthier S, Vinit J, Manckoundia P, Maillefert JF, Besancenot JF, Aho-Glele S, Olsson NO, Lorcerie B, Guillevin L, Mouthon L, Saas P, Bateman A, Martin L, Janikashvili N, Larmonier N, Bonnotte B.

Arthritis Rheum. 2012 Nov;64(11):3788-98. doi: 10.1002/art.34647.

21.

Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.

Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, Ornetti P, Maillefert JF, Miossec P, Bonnotte B.

Arthritis Rheum. 2012 Aug;64(8):2499-503. doi: 10.1002/art.34477.

22.

Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange.

Samson M, Audia S, Leguy V, Berthier S, Janikashvili N, Martin L, Bonnotte B, Lorcerie B.

Intern Med J. 2012 Jan;42(1):95-8. doi: 10.1111/j.1445-5994.2011.02591.x.

PMID:
22276560
23.

The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.

Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Clin Dev Immunol. 2011;2011:430394. doi: 10.1155/2011/430394. Epub 2011 Nov 3. Review.

24.

Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N.

J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.

25.

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.

Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, Ciudad M, Leguy V, Berthier S, Petrella T, Aho-Glélé S, Martin L, Maynadié M, Lorcerie B, Rat P, Cheynel N, Katsanis E, Larmonier N, Bonnotte B.

Blood. 2011 Oct 20;118(16):4394-400. doi: 10.1182/blood-2011-03-344051. Epub 2011 Aug 29.

26.

Cytotoxic dendritic cells generated from cancer patients.

Lakomy D, Janikashvili N, Fraszczak J, Trad M, Audia S, Samson M, Ciudad M, Vinit J, Vergely C, Caillot D, Foucher P, Lagrost L, Chouaib S, Katsanis E, Larmonier N, Bonnotte B.

J Immunol. 2011 Sep 1;187(5):2775-82. doi: 10.4049/jimmunol.1004146. Epub 2011 Jul 29.

27.

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E.

Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.

28.

Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease.

Larmonier CB, Midura-Kiela MT, Ramalingam R, Laubitz D, Janikashvili N, Larmonier N, Ghishan FK, Kiela PR.

Inflamm Bowel Dis. 2011 Feb;17(2):503-15. doi: 10.1002/ibd.21391.

29.

Personalized dendritic cell-based tumor immunotherapy.

Janikashvili N, Larmonier N, Katsanis E.

Immunotherapy. 2010 Jan;2(1):57-68. Review.

30.

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B.

J Immunol. 2010 Feb 15;184(4):1876-84. doi: 10.4049/jimmunol.0900831. Epub 2010 Jan 20.

31.

Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.

Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, J LaCasse C, Situ E, Larmonier N, Katsanis E.

Immunobiology. 2010 Jul;215(7):535-44. doi: 10.1016/j.imbio.2009.09.006. Epub 2009 Oct 31.

32.

Changes in mucosal homeostasis predispose NHE3 knockout mice to increased susceptibility to DSS-induced epithelial injury.

Kiela PR, Laubitz D, Larmonier CB, Midura-Kiela MT, Lipko MA, Janikashvili N, Bai A, Thurston R, Ghishan FK.

Gastroenterology. 2009 Sep;137(3):965-75, 975.e1-10. doi: 10.1053/j.gastro.2009.05.043. Epub 2009 May 18.

33.

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E.

J Immunol. 2008 Nov 15;181(10):6955-63.

34.

A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.

Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E.

Mol Cancer Ther. 2008 Mar;7(3):721-9. doi: 10.1158/1535-7163.MCT-07-2067.

35.

Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.

Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E.

J Leukoc Biol. 2008 Apr;83(4):1049-59. doi: 10.1189/jlb.0907635. Epub 2008 Jan 3.

PMID:
18174364
36.

The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B.

Exp Cell Res. 2007 Jul 1;313(11):2345-55. Epub 2007 Mar 30.

PMID:
17466973

Supplemental Content

Loading ...
Support Center